Loading organizations...
§ Private Profile · No. 27, Huanyu 1st Road, International Bio-Island, Guangzhou, China
A clinical-stage diagnostics company developing NGS products for early cancer screening and diagnosis of solid tumors.
Founded in 2015 by former Illumina executive Jian-Bing Fan, AnchorDx is a Guangzhou-based clinical-stage diagnostics company developing next-generation sequencing tests for early cancer screening, diagnosis, and recurrence monitoring. The organization utilizes proprietary circulating tumor DNA high-throughput methylation technology to identify biomarkers for high-incidence cancers, targeting lung, breast, and digestive system tumors. Prior to its September 2024 acquisition by Kindstar Globalgene Technology, the company operated with approximately 90 employees and generated an estimated $16.1 million in annual revenue. During its independent lifecycle, AnchorDx secured over $73 million in total venture funding, including a $40 million Series C round from prominent investors like OrbiMed and WuXi AppTec. To advance precision oncology, the firm established strategic partnerships with industry leaders such as Illumina and DiaCarta, and earned FDA Breakthrough Device Designation for its PulmoSeek lung cancer blood test.
AnchorDx has raised $68.0M across 2 funding rounds.
AnchorDx has raised $68.0M in total across 2 funding rounds.
AnchorDx has raised $68.0M in total across 2 funding rounds.
AnchorDx's investors include OrbiMed, WuXi Huiying Investment, 6 Dimensions Capital.
AnchorDx is a precision diagnostics company specializing in early cancer detection through ctDNA high-throughput methylation sequencing technology.[2][3] Founded in 2015 and headquartered in Guangzhou, China, with R&D centers in China and the US, it develops non-invasive products like "a tube of blood" and "a tube of urine" tests covering over 70% of high-incidence cancers, including lung, breast, digestive, and urinary system cancers, for screening, early diagnosis, recurrence monitoring, and companion diagnostics.[1][2][3] AnchorDx serves oncologists, hospitals, and patients by solving the challenge of detecting cancers at early stages when treatments are most effective, leveraging proprietary technologies such as AnchorIRIS® for DNA methylation profiling and an AI platform for lung cancer.[2][3][4] The company has shown strong growth through partnerships (e.g., with DiaCarta and Illumina), clinical trials like the Bell Program, product launches such as UriFind® for bladder cancer, and $43 million in Series A+ and B financing.[1][2]
AnchorDx was officially established in 2015 in Guangzhou International Bio Island, pioneering ctDNA methylation sequencing for tumor early detection in China.[2][3] Key founders and leaders include a global genetic technology expert and former Illumina chief scientist (employee #23), who led high-throughput sequencing developments and returned to China for precision medicine; Marina, with 20+ years in genomic technologies from Illumina, Grail, and Thermo Fisher; and other specialists in liquid biopsy and companion diagnostics.[2] The idea emerged from advancing non-invasive detection via blood and urine, starting with Guangzhou AnchorDx Medical Laboratory and early studies presented at CSCO and AACR conferences (first in China and world for certain methylation applications).[2] Pivotal moments include Series A financing ($5M) in 2015, strategic ties with Illumina and Fred Hutchinson Cancer Center, the Bell Program clinical trials with Academician Nanshan Zhong, LDT qualification as China's first NGS clinical lab, and $38M in A+ and B rounds.[2]
AnchorDx rides the liquid biopsy wave, leveraging ctDNA methylation for non-invasive early cancer detection amid rising global cancer burdens and demand for personalized medicine.[1][2][3] Timing aligns with advances in high-throughput sequencing (e.g., Illumina roots) and AI-driven diagnostics, enabling population-scale screening where traditional methods like imaging fall short.[2][4] Market forces favoring it include China's precision medicine push, regulatory nods (e.g., national genetic testing center), and partnerships accelerating global reach amid aging populations and high lung/colorectal cancer rates.[2] It influences the ecosystem by publishing in top journals (e.g., Journal of Clinical Investigation, NPJ Breast Cancer), licensing patents, and validating methylation in prospective trials, paving the way for pan-cancer tools and reducing late-stage diagnoses.[2][3][4]
AnchorDx is poised for global expansion via partnerships like DiaCarta and ongoing trials (e.g., Thunder Project, Angel-2), potentially launching more pan-cancer blood/urine tests and scaling its AI platform.[1][3] Trends like multi-omics integration, regulatory harmonization (e.g., FDA/CLIA), and AI enhancements will shape its path, boosting sensitivity for minimal residual disease monitoring. Its influence may evolve from China pioneer to worldwide leader, commercializing IP amid a $10B+ liquid biopsy market, building on methylation's edge over mutation-based rivals for earlier detection. This positions AnchorDx to transform "better diagnostics, better life" from vision to standard care.[2][3]
AnchorDx has raised $68.0M across 2 funding rounds. Most recently, it raised $40.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 23, 2021 | $40M Series C | OrbiMed, Wuxi Huiying Investment | — | Announced |
| Nov 1, 2017 | $28M Series B | — | 6 Dimensions Capital | Announced |